1,2,3,4,6-Penta-O -Galloyl-Beta-D-Glucopyranoside Inhibits Proliferation of Multiple Myeloma Cells Accompanied with Suppression of MYC Expression

Frontiers in Pharmacology
Duurenjargal TseeleesurenYi-Ming A Chen

Abstract

Multiple myeloma (MM) still remains an incurable disease, therefore discovery of novel drugs boosts the therapeutics for MM. The natural compound 1,2,3,4,6-Penta-O-galloyl-beta-D-glucopyranoside (PGG) has been shown to exhibit antitumor activities against various cancer cells. Here, we aim to evaluate antitumor effects of PGG on MM cell lines. PGG inhibited the growth of three different MM cell lines in a dose- and time-dependent manner. Cell cycle analysis revealed that PGG treatment caused cell cycle arrest in G1 phase. It also induced apoptosis which was indicated by significant increases of Annexin V positive cells, caspase 3/7 activity, and cleaved caspase 3 expression in PGG treated MM cell. Since MYC is frequently hyperactivated in MM and inhibition of MYC leads to MM cell death. We further demonstrated that PGG decreased MYC expression in protein and mRNA levels and reversed the mRNA expression of MYC target genes such as p21, p27, and cyclin D2. In addition, PGG also reduced protein expression of DEPTOR which is commonly overexpressed in MM. Unexpectedly, PGG antagonized the cytotoxic effect of bortezomib in the combination treatment. However, PGG treatment sensitized MM cells to another proteasome inhibitor MG132 indu...Continue Reading

References

Feb 1, 1987·Chemical & Pharmaceutical Bulletin·K MiyamotoT Okuda
Apr 15, 2004·American Journal of Clinical Pathology·Pei LinCarla S Wilson
Aug 2, 2008·International Immunopharmacology·Simone Campos Cavalher-MachadoMaria das Graças Müller de Oliveira Henriques
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
May 15, 2010·Medical Oncology·Francesca Gay, Antonio Palumbo
Dec 29, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Michel de WeersPaul W H I Parren
Sep 6, 2011·Cell·Jake E DelmoreConstantine S Mitsiades
Feb 22, 2012·Nature Reviews. Clinical Oncology·Anuj MahindraKenneth Anderson
May 31, 2012·Blood·Philippe MoreauJean-Luc Harousseau
Jun 26, 2012·Seminars in Hematology·Prashant KapoorS Vincent Rajkumar
Jul 19, 2012·Blood·Toril HolienAnders Sundan
Sep 12, 2012·Oncotarget·Toril Holien, Anders Sundan
Mar 16, 2013·Clinical Medicine Insights. Oncology·Utkarsh Painuly, Shaji Kumar
Aug 3, 2013·Cold Spring Harbor Perspectives in Medicine·Chi V Dang
Dec 19, 2013·Cancer Biology & Medicine·Li Jia, Feng-Ting Liu
Apr 4, 2015·Blood·Philippe MoreauThierry Facon
Aug 27, 2015·Scientific Reports·Virginie Follin-ArbeletHeidi Kiil Blomhoff
Aug 27, 2015·The New England Journal of Medicine·Henk M LokhorstPaul G Richardson
Jun 8, 2017·Genes·Manpreet KalkatLinda Z Penn

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
Assay
Protein Assay
PCR
PCA-1

Software Mentioned

GraphPad Prism
MS excel

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

© 2022 Meta ULC. All rights reserved